{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:52:32Z","timestamp":1791251552224,"version":"4.1.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.1001\/jamaoncol.2020.4338","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T11:39:01Z","timestamp":1600947541000},"page":"1759","source":"Crossref","is-referenced-by-count":104,"title":["Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors"],"prefix":"10.1001","volume":"6","author":[{"given":"Smith","family":"Giri","sequence":"first","affiliation":[{"name":"Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology, University of Alabama at Birmingham"},{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Grimshaw","sequence":"additional","affiliation":[{"name":"Harvey Cushing\/John Hay Whitney Medical Library, Yale University, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Godby","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Kharel","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Geisinger Health System, Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[{"name":"Evidence-based Analytics and Comparative Effectiveness Research, Department of Supportive Care, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Section of Hematology and Medical Oncology, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"Department of Hematology, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Plasma Cell Disorders Program, Levine Cancer Institute\/Atrium Health, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospital of Salamanca\/IBSAL, Cancer Research Center, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"15","key":"coi200069r1","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"coi200069r2","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from International Myeloma Working Group.","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi200069r3","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/leu.2014.232","article-title":"Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma.","volume":"28","author":"Heuck","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"coi200069r4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.","volume":"121","author":"Bergsagel","year":"2013","journal-title":"Blood"},{"issue":"6","key":"coi200069r5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41375-018-0098-9","article-title":"Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents.","volume":"32","author":"Avet-Loiseau","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"coi200069r6","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du My\u00e9lome experience.","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J Clin Oncol"},{"issue":"14","key":"coi200069r7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline.","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"13","key":"coi200069r8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma.","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"10218","key":"coi200069r9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet."},{"issue":"22","key":"coi200069r10","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma.","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"coi200069r11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma.","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"10192","key":"coi200069r12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"coi200069r14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma.","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"coi200069r15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"coi200069r17","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"coi200069r20","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"coi200069r21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS peer review of electronic search strategies: 2015 guideline statement.","volume":"75","author":"McGowan","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"coi200069r22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13643-019-1069-6","article-title":"Usability and acceptability of four systematic review automation software packages: a mixed method design.","volume":"8","author":"Cleo","year":"2019","journal-title":"Syst Rev"},{"key":"coi200069r23","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"coi200069r24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: a time for change.","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"issue":"Pt A","key":"coi200069r25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cct.2015.05.009","article-title":"Advances in the meta-analysis of heterogeneous clinical trials, I: the inverse variance heterogeneity model.","volume":"45","author":"Doi","year":"2015","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"coi200069r26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"coi200069r27","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"issue":"6","key":"coi200069r28","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/leu.2016.390","article-title":"Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.","volume":"31","author":"Chng","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"coi200069r29","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma.","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"24","key":"coi200069r30","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","article-title":"Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients.","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"issue":"20","key":"coi200069r31","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1200\/JCO.2013.53.0329","article-title":"Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and\/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.","volume":"32","author":"Moreau","year":"2014","journal-title":"J Clin Oncol"},{"issue":"24","key":"coi200069r32","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"7","key":"coi200069r33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ajh.24389","article-title":"Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients.","volume":"91","author":"R\u00edos-Tamayo","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"coi200069r34","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/ejh.2019.103.issue-2","article-title":"Understanding mortality in multiple myeloma: findings of a European retrospective chart review.","volume":"103","author":"Mohty","year":"2019","journal-title":"Eur J Haematol"},{"key":"coi200069r13","author":"Bahlis","year":"2019"},{"key":"coi200069r16","author":"Usmani","year":"2019"},{"key":"coi200069r18","author":"Kaufman","year":"2019"},{"key":"coi200069r19","author":"Weisel","year":"2019"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2770699\/jamaoncology_giri_2020_oi_200069_1604947265.21351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T12:44:30Z","timestamp":1605185070000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2770699"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.4338","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,1]]}}}